Atea Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trials for Novel Hepatitis C Treatment
Table of Contents
Atea Pharmaceuticals (Nasdaq: AVIR) announced the completion of patient enrollment in both its C-BEYOND and C-FORWARD Phase 3 trials, representing a significant milestone in the development of a new treatment for Hepatitis C virus (HCV).
Boston, December 22, 2025 – Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, has reached a critical juncture in its pursuit of a best-in-class HCV treatment. The company announced today the successful enrollment of over 880 treatment-naïve patients in the C-BEYOND trial, conducted in the United States and Canada, and continues to enroll patients in the C-FORWARD trial, spanning up to 17 countries outside of North America.
Advancing a New Treatment Paradigm for HCV
The C-BEYOND and C-FORWARD trials are groundbreaking as the first global Phase 3 head-to-head studies evaluating direct-acting antivirals (DAAs) for HCV treatment. Both trials are assessing a fixed-dose combination (FDC) regimen of bemnifosbuvir and ruzasvir against the established regimen of sofosbuvir and velpatasvir. The Atea regimen offers a potentially shorter treatment duration – eight weeks for patients without cirrhosis and 12 weeks for those with compensated cirrhosis – compared to the standard 12-week course of sofosbuvir and velpatasvir.
“Completing enrollment in C-BEYOND marks a critical inflection point in our Phase 3 HCV program and we are on track to deliver topline results from this trial mid-2026,” stated Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, in a company release. “Our goal is and has always been to develop a best-in-class HCV treatment that meaningfully advances the standard of care.”
Trial Details and Expected Timelines
The C-BEYOND trial is being conducted across approximately 120 clinical trial sites in the US and Canada, while C-FORWARD involves roughly 120 sites internationally. Both trials are designed to evaluate the efficacy and safety of the Atea regimen in treatment-naïve patients, including those with and without compensated cirrhosis.
Key timelines for the trials include:
- C-BEYOND Topline Results: Expected mid-year 2026
- C-FORWARD Enrollment Completion: Expected mid-year 2026
- C-FORWARD Topline Results: Anticipated year-end 2026
The primary endpoint for both trials is achieving undetectable HCV RNA levels at 24 weeks post-treatment, indicating a sustained virologic response 12 weeks post-treatment (SVR12).
Addressing Unmet Needs in HCV Treatment
Despite the availability of DAAs, HCV remains a significant global health challenge. An estimated 50 million people worldwide are chronically infected, with approximately one million new infections occurring annually. In the United States alone, up to 4 million individuals live with chronic HCV, and diagnoses continue to exceed cure rates.
According to healthcare providers, approximately 80% of HCV patients are managing multiple medications for co-existing conditions, and concerns about drug-drug interactions are a major factor delaying treatment. Atea’s regimen is designed to address these concerns with a low risk of drug interactions, a convenient once-daily oral administration, and no food effect.
“A new treatment option offering high efficacy, short treatment duration, and a low risk of drug-drug interactions could meaningfully help to address patient needs and further the goal of HCV eradication,” a company spokesperson noted.
Atea Pharmaceuticals is focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral infections. The company’s expertise in antiviral drug development positions it to potentially deliver a significant advancement in the treatment of HCV and address the evolving needs of patients worldwide.
